Inovio Pharmaceuticals Inc (NASDAQ:INO) has earned an average recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $6.69.
INO has been the subject of several analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Inovio Pharmaceuticals in a report on Sunday, August 11th. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 18th. Citigroup reaffirmed a “buy” rating and issued a $4.00 price objective (down from $7.00) on shares of Inovio Pharmaceuticals in a report on Monday, September 16th. ValuEngine raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Piper Jaffray Companies dropped their price objective on Inovio Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, July 17th.
In other news, Director David B. Weiner sold 16,352 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $2.72, for a total transaction of $44,477.44. Following the completion of the transaction, the director now owns 797,110 shares of the company’s stock, valued at approximately $2,168,139.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.90% of the stock is currently owned by insiders.
INO traded down $0.12 during trading on Friday, hitting $2.24. The stock had a trading volume of 42,917 shares, compared to its average volume of 496,539. The company has a 50 day moving average price of $2.24 and a 200-day moving average price of $2.86. The firm has a market cap of $221.82 million, a price-to-earnings ratio of -2.16 and a beta of 2.07. Inovio Pharmaceuticals has a one year low of $1.91 and a one year high of $5.68. The company has a debt-to-equity ratio of 1.49, a current ratio of 4.59 and a quick ratio of 4.59.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02). The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 142.10%. During the same period in the prior year, the firm earned ($0.07) earnings per share. As a group, sell-side analysts predict that Inovio Pharmaceuticals will post -1.06 EPS for the current fiscal year.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.